A. Brodie

发表

W. Yue, A. Brodie, S. Inkster, 2001, Molecular and Cellular Endocrinology.

Mechanisms of the actions of aromatase inhibitors 4-hydroxyandrostenedione, fadrozole, and aminoglutethimide on aromatase in JEG-3 cell culture

W. Yue, A. Brodie, Wei Yue, 1997, The Journal of Steroid Biochemistry and Molecular Biology.

Aromatase, aromatase inhibitors, and breast cancer

A. Brodie, Timothy R. Howes, T. Bao, 2011, The Journal of Steroid Biochemistry and Molecular Biology.

Aromatase inhibitor development and hormone therapy: a perspective.

A. Brodie, 2003, Seminars in oncology.

Aromatase inhibitors in advanced breast cancer: mechanism of action and clinical implications

V. Njar, A. Brodie, 1998, The Journal of Steroid Biochemistry and Molecular Biology.

Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?

P. Lønning, P. Goss, J. Bartlett, 2008, The oncologist.

The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer.

A. Brodie, A. A. Shaikh, H. Brodie, 1977, Endocrinology.

Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo

C. Tsai-Morris, W. Garrett, P. Marcotte, 1981, Steroids.

Aromatase inhibitors. Synthesis and biological activity of androstenedione derivatives.

C. Tsai-Morris, W. Garrett, A. Brodie, 1985, Journal of medicinal chemistry.

Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route.

T. Powles, M. Dowsett, R. Coombes, 1987, Cancer research.

An aromatase-producing sex-cord tumor resulting in prepubertal gynecomastia.

R. Santen, R. Zaino, H. Kulin, 1991, The New England journal of medicine.

Endocrine and targeted manipulation of breast cancer: Summary statement for the Sixth Cambridge Conference

E. Winer, R. Coombes, A. Buzdar, 2008, Cancer.

Aromatase and its inhibitors in breast cancer treatment — overview and perspective

R. Santen, A. Brodie, 2004, Breast Cancer Research and Treatment.

Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR

V. Njar, A. Brodie, A. Brodie, 2010, British Journal of Cancer.

Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.

F. Huang, P. Haluska, M. Gottardis, 2011, Cancer research.

Anti-HER 2 immunoliposomes for selective delivery of electron paramagnetic resonance imaging probes to HER 2-overexpressing breast tumor cells

J. Kao, H. Halpern, A. Brodie, 2010 .

Anti-HER2 immunoliposomes for selective delivery of electron paramagnetic resonance imaging probes to HER2-overexpressing breast tumor cells

J. Kao, H. Halpern, A. Brodie, 2010, Breast Cancer Research and Treatment.

The relationship between aromatase in primary breast tumors and response to treatment with aromatase inhibitors in advanced disease

J. Nortier, M. Blankenstein, J. Thijssen, 2003, The Journal of Steroid Biochemistry and Molecular Biology.

Aromatase inhibitors in breast cancer

A. Brodie, 2002, Trends in Endocrinology & Metabolism.

The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.

A. Brodie, A. Thiantanawat, B. Long, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Aromatase inhibitors and models for breast cancer

A. Brodie, 2008 .

Aromatase Inhibitors and Their Application to the Treatment of Breast Cancer

A. Brodie, 2002 .

The aromatase inactivator 4-hydroxyandrostenedione (4-OH-A) inhibits tamoxifen metabolism by rat hepatic cytochrome P-450 3A: potential for drug-drug interaction of tamoxifen and 4-OH-A in combined anti-breast cancer therapy.

S. Dehal, A. Brodie, D. Kupfer, 1999, Drug metabolism and disposition: the biological fate of chemicals.

Extending aromatase inhibitor sensitivity in hormone resistant breast cancer

A. Brodie, S. Chumsri, G. Sabnis, 2011, Hormone molecular biology and clinical investigation.

Aromatase Inhibitors for Breast Cancer Prevention

A. Brodie, S. Chumsri, Stephen Yu, 2016 .

Aromatase inhibitors and breast cancer

A. Brodie, S. Chumsri, 1996, Hormone molecular biology and clinical investigation.

Steroidogenic enzyme inhibitors and hormone dependent cancer

T. Vasaitis, V. Njar, A. Brodie, 2009 .

Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model.

W. Yue, Jiping Wang, A. Brodie, 1995, Cancer research.

Inhibitory effects of retinoic acid metabolism blocking agents (RAMBAs) on the growth of human prostate cancer cells and LNCaP prostate tumour xenografts in SCID mice

V. Njar, A. Brodie, A. Brodie, 2006, British Journal of Cancer.

Estrogen regulates vascular endothelial growth/permeability factor expression in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors.

A. Brodie, Q. Lu, Q. Lu, 1996, Endocrinology.

The effect of aromatase inhibitor 4-hydroxyandrostenedione on steroid receptors in hormone-dependent tissues of the rat

A. Brodie, Jiang Zhou, 1995, The Journal of Steroid Biochemistry and Molecular Biology.

Detection of aromatase and keratinocyte growth factor expression in breast tumors using reverse transcription-polymerase chain reaction

W. Yue, A. Brodie, S. Inkster, 1993, The Journal of Steroid Biochemistry and Molecular Biology.

Use of tissue-specific promoters in the regulation of aromatase cytochrome P450 gene expression in human testicular and ovarian sex cord tumors, as well as in normal fetal and adult gonads.

S. Bulun, E. Simpson, M. Kilgore, 1993, The Journal of clinical endocrinology and metabolism.

Aromatase inhibitors and their application in breast cancer treatment☆

V. Njar, A. Brodie, 2000, Steroids.

Aromatase and its inhibitors

A. Brodie, B. Long, Q. Lu, 1999, The Journal of Steroid Biochemistry and Molecular Biology.

Differential responses of sex steroid target tissues of rats treated with 4-hydroxyandrostenedione.

A. Brodie, J. Hammond, L. Wing, 1988, Endocrinology.

The dual IGF-1 R / InsR inhibitor , BMS-754807 , demonstrates synergy in combination with hormonal agents in vitro and enhances in vivo activity in an estrogen-dependent breast cancer model

F. Huang, P. Haluska, M. Gottardis, 2011 .

Therapeutics , Targets , and Chemical Biology Dual IGF-1 R / InsR Inhibitor BMS-754807 Synergizes with Hormonal Agents in Treatment of Estrogen-Dependent Breast Cancer

F. Huang, P. Haluska, M. Gottardis, 2011 .

Effect of an aromatase inhibitor (4-acetoxy-4-androstene-3,17-dione) on the stimulatory action of luteinizing hormone on estradiol-17 beta synthesis by rat preovulatory follicles in vitro.

P. Leung, D. Armstrong, G. Evans, 1981, Biology of reproduction.

Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer

N. Davidson, Qun Zhou, T. Kensler, 2010, Breast Cancer Research and Treatment.

Comprehensive Pharmacology and Clinical Efficacy of Aromatase Inhibitors

V. Njar, A. Brodie, 1999, Drugs.

Immunocytochemical studies of aromatase in early and full-term human placental tissues: comparison with biochemical assays.

A. Brodie, S. Inkster, 1989, Biology of reproduction.

Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway Improves Response of Long-term Estrogen-Deprived Breast Cancer Xenografts to Antiestrogens

A. Brodie, O. Goloubeva, G. Sabnis, 2007, Clinical Cancer Research.

Androgen receptor inactivation contributes to antitumor efficacy of 17A-hydroxylase/17,20-lyase inhibitor

Zhiyong Guo, Hong-Bin Fang, A. Khandelwal, 2008 .

Aromatase in breast cancer and the role of aminoglutethimide and other aromatase inhibitors.

R. Santen, A. Brodie, 1986, Critical reviews in oncology/hematology.

Aromatase and its inhibitors—an overview

A. Brodie, 1991, The Journal of Steroid Biochemistry and Molecular Biology.

4-Hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer

M. Dowsett, R. Coombes, P. Goss, 1987, Steroids.

Metabolism of the aromatase inhibitor 4-hydroxy-4-androstene-3,17-dione by male rhesus monkeys.

A. Brodie, L. Romanoff, K. I. Williams, 1981, Journal of steroid biochemistry.

Inhibition of estrogen biosynthesis and regression of mammary tumors by aromatase inhibitors.

J. Williams, A. Brodie, H. Brodie, 1981, Advances in experimental medicine and biology.

Lack of evidence for aromatase in human prostatic tissues: effects of 4-hydroxyandrostenedione and other inhibitors on androgen metabolism.

A. Brodie, S. Inkster, K. Meyer, 1989, Cancer research.

Aromatase inhibitors as new endocrine therapy for breast cancer.

M. Dowsett, R. Coombes, A. Brodie, 1988, Cancer treatment and research.

In vitro and in vivo studies with aromatase inhibitor 4-hydroxyandrostenedione

A. Brodie, Wing Lih-Yuh, 1987, Steroids.

Aromatase inhibitors: basic and clinical studies.

M. Dowsett, R. Coombes, A. Brodie, 1987, Journal of steroid biochemistry.

Aromatase inhibitors--IV. Regression of hormone-dependent, mammary tumors in the rat with 4-acetoxy-4-androstene-3,17-dione.

A. Brodie, H. Brodie, D. Marsh, 1979, Journal of steroid biochemistry.

Effect of an aromatase inhibitor, 1,4,6-androstatriene-3,17-dione, on 7,12-dimethylbenz[a]anthracene-induced mammary tumors in the rat and its mechanism of action in vivo.

C. Tsai-Morris, W. Garrett, A. Brodie, 1982, Biochemical pharmacology.

Aromatase inhibitors III. Studies on the antifertility effect of 4-acetoxy-4-androstene-3,17-dione.

A. Brodie, H. Brodie, J. Wu, 1978, Biology of reproduction.

Studies on the mechanism of estrogen biosynthesis in the rat ovary--I.

A. Brodie, H. Brodie, W. C. Schwarzel, 1976, Journal of steroid biochemistry.

Expression of aromatase protein and messenger ribonucleic acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers.

D. Dabbs, W. Yue, G. Wolz, 1996, Endocrinology.

Aromatase in the normal breast and breast cancer

A. Brodie, Q. Lu, J. Nakamura, 1997, The Journal of Steroid Biochemistry and Molecular Biology.

Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.

V. Njar, A. Brodie, A. Belosay, 2006, Cancer research.

Njar ( VN / 14-1 ) on Letrozole-Insensitive Breast Cancer Cells Effects of Novel Retinoic Acid Metabolism Blocking Agent

A. Brodie, O. VincentC., 2006 .

Design, Synthesis and Evaluation of Growth Regulating SDF-1 Peptides on Breast Carcinoma Cells

A. Brodie, Sandra C. Vigil-Cruz, Megan K. Condon, 2001 .

Somatomedin-C-mediated potentiation of follicle-stimulating hormone-induced aromatase activity of cultured rat granulosa cells.

E. Adashi, J. V. Van Wyk, A. Brodie, 1985, Endocrinology.

Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.

L. Gediya, O. Clement, V. Njar, 2004, Journal of medicinal chemistry.

MCF-7 human breast carcinomas in nude mice as a model for evaluating aromatase inhibitors

W. Yue, A. Brodie, 1993, The Journal of Steroid Biochemistry and Molecular Biology.

Treatment Strategies Using Letrozole and Tamoxifen in a Xenograft Model for Breast Cancer

A. Brodie, B. Long, A. Brodie, 2003 .

Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth

A. Khandelwal, V. Njar, A. Brodie, 2007, British Journal of Cancer.

The effect of estrogen on aromatase and vascular endothelial growth factor messenger ribonucleic acid in the normal nonhuman primate mammary gland.

A. Brodie, Q. Lu, E. Albrecht, 1999, The Journal of clinical endocrinology and metabolism.

Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis.

G. Klus, E. Wilson, J. A. Kemppainen, 1996, Cancer research.

Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy.

Rolf W Hartmann, R. Hartmann, T. Vasaitis, 2003, Journal of medicinal chemistry.

17-Imidazolyl, pyrazolyl, and isoxazolyl androstene derivatives. Novel steroidal inhibitors of human cytochrome C17,20-lyase (P450(17 alpha).

G. Klus, Katsuya Kato, A. Brodie, 1997, Journal of medicinal chemistry.

A versatile synthesis of 17-heteroaryl androstenes via palladium-mediated Suzuki cross-coupling with heteroaryl boronic acids

Xiaofeng Liu, A. Brodie, J. Chao, 2006, Steroids.

17α-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response

R. D. Bruno, V. Njar, T. Gover, 2008, Molecular Cancer Therapeutics.

Structure of 4-hydroxy-4-androstene-3,17-dione

W. Duax, A. Brodie, J. Griffin, 1980 .

Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors

W. Miller, D. Evans, A. Brodie, 2001, The Journal of Steroid Biochemistry and Molecular Biology.

Aromatase activity in cultured human genital skin fibroblasts.

C. Migeon, G. Berkovitz, T. Brown, 1984, The Journal of clinical endocrinology and metabolism.

Comparison of the effect of 4-hydroxy-4-androstene-3, 17-dione on aromatose activity in granulosa cells from preovulatory follicles of rats, rabbits, and humans

A. Brodie, R. Koos, W. LeMaire, 1985, Steroids.

Recent advances in studies on estrogen biosynthesis

A. Brodie, 1979, Journal of endocrinological investigation.

The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity

D. Grigoryev, W. Yue, Syreeta L. Tilghman, 1998, The Journal of Steroid Biochemistry and Molecular Biology.

Overview of recent development of aromatase inhibitors.

A. Brodie, 1982, Cancer research.

Regulation of microsomal P450, redox partner proteins, and steroidogenesis in the developing testes of the neonatal pig.

V. Njar, C. Corbin, A. Conley, 2002, Endocrinology.

Aromatase in the human testis

A. Brodie, S. Inkster, 1993, The Journal of Steroid Biochemistry and Molecular Biology.

Inhibition of androgen synthesis by 22‐hydroximino‐23,24‐bisnor‐4‐cholen‐3‐one

A. Brodie, C. Son, J. Li, 1995, The Prostate.

Aromatase inhibitors in the treatment of breast cancer

A. Brodie, Angela M. H. Brodie, 1994, The Journal of Steroid Biochemistry and Molecular Biology.

Human testicular aromatase: immunocytochemical and biochemical studies.

W. Yue, A. Brodie, S. Inkster, 1995, The Journal of clinical endocrinology and metabolism.

Intrauterine Growth Retardation Associated with Precocious Puberty and Sertoli Cell Hyperplasia

M. Merino, C. Stratakis, M. Lodish, 2010, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

The aromatase excess syndrome is associated with feminization of both sexes and autosomal dominant transmission of aberrant P450 aromatase gene transcription.

G. Chrousos, C. Mitsiades, C. Stratakis, 1998, The Journal of clinical endocrinology and metabolism.

Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): Head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model

P. Purushottamachar, L. Gediya, T. Vasaitis, 2011, Steroids.

Novel P45017α inhibitors: 17-(2′-oxazolyl)- and 17-(2′-thiazolyl)-androstene derivatives

A. Brodie, Venkatesh D. Handratta, Y. Ling, 2003, Steroids.

Aromatase inhibitors and their use in controlling oestrogen-dependent processes.

A. Brodie, H. Brodie, J. Wu, 1979, Journal of steroid biochemistry.

Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens.

A. Brodie, A. Thiantanawat, B. Long, 2003, Cancer research.

Aromatase inhibitors prevent granulosa cell differentiation: an obligatory role for estrogens in luteinizing hormone receptor expression.

K. Catt, A. Brodie, M. Knecht, 1985, Endocrinology.

Mechanistic Relationship between Androgen Receptor Polyglutamine Tract Truncation and Androgen-dependent Transcriptional Hyperactivity in Prostate Cancer Cells*

T. Vasaitis, Qianben Wang, J. Fondell, 2004, Journal of Biological Chemistry.

Inhibition of ovarian aromatase by prolactin in vivo.

C. Tsai-Morris, P. Wise, A. Brodie, 1983, Biology of reproduction.

Biochemical Assessment of Limits to Estrogen Synthesis in Porcine Follicles1

V. Njar, C. Corbin, A. Conley, 2003, Biology of reproduction.

Role of FSH and oestradiol-17 beta in the development of meiotic competence in rat oocytes.

A. Brodie, A. Tsafriri, S. Bar-ami, 1983, Journal of steroid biochemistry.

Prepubertal gynaecomastia caused by medication or the aromatase excess syndrome

C. Stratakis, D. Batista, A. Brodie, 2004, Clinical Endocrinology.

Aromatease, its inhibitors and their use in breast cancer treatment

A. Brodie, 1993 .

Inhibition of peripheral aromatization by aromatase inhibitors, 4-hydroxy- and 4-acetoxy-androstene-3,17-dione.

C. Longcope, A. Brodie, 1980, Endocrinology.

Erratum: Use of tissue-specific promoters in the regulation of aromatase cytochrome P450 gene expression in human testicular and ovarian sex cord tumors, as well as in normal fetal and adult gonads (Journal of Clinical Endocrinology and Metabolism (1993) 77 (1616-1621))

S. Bulun, E. Simpson, M. Kilgore, 1994 .

Inhibition of estrogen synthesis does not inhibit luteinizing hormone-induced ovulation.

A. Brodie, R. Koos, W. LeMaire, 1984, American journal of obstetrics and gynecology.

Effect of 4-Hydroxyandrostenedione on 19-hydroxylation of deoxycorticosterone in the golden syrian hamster

J. Melby, A. Brodie, M. Holbrook, 1988, Steroids.

Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.

V. Njar, A. Brodie, 2015, Journal of medicinal chemistry.

Androgen receptor inactivation contributes to antitumor efficacy of 17α-hydroxylase/17,20-lyase inhibitor 3β-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer

Hong-Bin Fang, Pankaj Chopra, Zhiyong Guo, 2008, Molecular Cancer Therapeutics.

Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.

Pankaj Chopra, Zhiyong Guo, P. Chopra, 2005, Journal of medicinal chemistry.

Nuclear maturation of follicle-enclosed rat oocytes during inhibition of steriodogenesis

A. Brodie, H. Billig, A. Tsafriri, 1983 .

Regulation of ovarian steroid biosynthesis by estrogen during proestrus in the rat.

A. Brodie, K. Meyer, P. Banks, 1991, Endocrinology.

Aromatase inhibitors and the treatment of breast cancer.

M. Dowsett, R. Coombes, P. Goss, 1986, Journal of steroid biochemistry.

Aromatase inhibition and its pharmacologic implications.

A. Brodie, 1985, Biochemical pharmacology.

Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report.

T. Powles, M. Dowsett, R. Coombes, 1986, Cancer research.

Effects of aromatase inhibitors, aminoglutethimide, and 4-hydroxyandrostenedione on cyclic rats and rats with 7,12-dimethylbenz(a)anthracene-induced mammary tumors.

W. Garrett, A. Brodie, L. Wing, 1985, Cancer research.

Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17α-Hydroxylase-C17,20-lyase (P45017α) : Potential agents for the treatment of prostate cancer

Katsuya Kato, Dmitry N. Grigoryev, V. Njar, 1998 .

Advances in mechanisms of resistance to aromatase inhibitors

A. Brodie, S. Chumsri, G. Sabnis, 2014, Expert review of anticancer therapy.

Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.

D. Grigoryev, A. Brodie, B J Long, 2000, Cancer research.

Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: summary consensus statement.

A. Buzdar, J. Ingle, P. Goss, 2001, Clinical Cancer Research.

Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model.

J. Ragaz, N. Macpherson, A. Brodie, 2004, Journal of the National Cancer Institute.

Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro

Gauri Sabnis, V. Njar, A. Brodie, 2008, Molecular Cancer Therapeutics.

Model systems: Mechanisms involved in the loss of sensitivity to letrozole

A. Brodie, B. Long, O. Goloubeva, 2005, The Journal of Steroid Biochemistry and Molecular Biology.

Aromatase, its inhibitors and their use in breast cancer treatment.

A. Brodie, 1993, Pharmacology & therapeutics.

Effects of the Antiestrogen Tamoxifen and the Aromatase Inhibitor Letrozole on Serum Hormones and Bone Characteristics in a Preclinical Tumor Model for Breast Cancer

D. Berrigan, J. C. Barrett, S. Perkins, 2004, Clinical Cancer Research.

Aromatase inhibitors and hormone-dependent cancers

M. Dowsett, R. Coombes, A. Brodie, 1990, The Journal of Steroid Biochemistry and Molecular Biology.

Synthesis of novel 21-trifluoropregnane steroids: Inhibitors of 17α-hydroxylase/17,20-lyase (17α-lyase)

G. Klus, V. Njar, A. Brodie, 1997, Steroids.

mTOR inhibitors: changing landscape of endocrine-resistant breast cancer.

A. Brodie, K. Tkaczuk, S. Chumsri, 2014, Future oncology.

Xenograft models for aromatase inhibitor studies

A. Brodie, G. Sabnis, L. Macedo, 2007, The Journal of Steroid Biochemistry and Molecular Biology.

Aromatase and breast cancer

A. Brodie, G. Sabnis, D. Jelovac, 2006, The Journal of Steroid Biochemistry and Molecular Biology.

Peritoneal Fluid Biochemistry in Infertile Women with Mild Pelvic Endometriosis

E. Mackay, A. Brodie, S. Khoo, 1986, Australian and New Zealand journal of obstetrics and gynaecology.

Effects of testosterone, estradiol, aromatase inhibitor, gonadotropin and prolactin on the response of mouse testes to acute gonadotropin stimulation.

A. Bartke, A. Brodie, S. Dalterio, 1983, Journal of steroid biochemistry.

Expression of aromatase cytochrome P-450 in premenopausal and postmenopausal human ovaries: an immunocytochemical study.

A. Brodie, S. Inkster, 1991, The Journal of clinical endocrinology and metabolism.

Use of tissue-specific promoters in the regulation of aromatase cytochrome P450 gene expression in human testicular and ovarian sex cord tumors, as well as in normal fetal and adult gonads.

S. Bulun, E. Simpson, M. Kilgore, 1994, The Journal of clinical endocrinology and metabolism.

Aromatase inhibitors and their potential clinical significance.

M. Dowsett, R. Coombes, P. Goss, 1986, Journal of steroid biochemistry.

1. Estrogen antagonists. Aromatase inhibitors, their pharmacology and application.

C. Tsai-Morris, J. Williams, W. Garrett, 1983, Journal of steroid biochemistry.

The effect of tamoxifen on the pharmacokinetics of letrozole in female rats

A. Brodie, I. Nnane, X. Tao, 2006, Biopharmaceutics & drug disposition.

Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model

V. Njar, A. Brodie, B. Long, 2004, The Journal of Steroid Biochemistry and Molecular Biology.

Synthesis of new steroidal isoxazoles: inhibitors of estrogen synthase.

A. Brodie, E. Parish, C. Rodriguez-Valenzuela, 1998, Bioorganic & medicinal chemistry.

The influence of 4-hydroxy-4-androstene-3,17-dione on androgen metabolism and action in cultured human foreskin fibroblasts.

C. Migeon, G. Berkovitz, T. Brown, 1987, Journal of steroid biochemistry.

4-pregnene-3-one-20β-carboxaldehyde: A potent inhibitor of 17α-hydroxylase/C17,20-lyase and of 5α-reductase

A. Brodie, Yan Li, C. Son, 1992, The Journal of Steroid Biochemistry and Molecular Biology.

Anti-tumour effects and pharmacokinetic profile of 17-(5′ -isoxazolyl)androsta-4,16-dien-3-one (L-39) in mice: an inhibitor of androgen synthesis

D. Grigoryev, A. Brodie, B. Long, 2000, British Journal of Cancer.

Effects of novel 17-azolyl compounds on androgen synthesis in vitro and in vivo

V. Njar, Q. Lu, A. Brodie, 1999, The Journal of Steroid Biochemistry and Molecular Biology.

Inhibition of androgen synthesis in human testicular and prostatic microsomes and in male rats by novel steroidal compounds.

Q. Lu, A. Brodie, B. Long, 1999, Endocrinology.

Synthesis and in vitro activity of some epimeric 20α-hydroxy, 20-oxime and aziridine pregnene derivatives as inhibitors of human 17α-hydroxylase/c 17,20 -lyase and 5α-reductase

G. Klus, Katsuya Kato, A. Brodie, 1998 .

Aromatase inhibitors, their pharmacology and application

C. Tsai-Morris, J. Williams, W. Garrett, 1983 .

Novel P450(17alpha) inhibitors: 17-(2'-oxazolyl)- and 17-(2'-thiazolyl)-androstene derivatives.

A. Brodie, Venkatesh D. Handratta, Y. Ling, 2003, Steroids.

Docetaxel Followed by Castration Improves Outcomes in LNCaP Prostate Cancer–Bearing Severe Combined Immunodeficient Mice

A. Hussain, A. Brodie, O. Goloubeva, 2006, Clinical Cancer Research.

Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer

Adrian V. Lee, E. Winer, M. Dowsett, 2003 .

Effect of 1,4,6-androstatriene-3,17-dione (ATD), 4-hydroxy-4-androstene-3,17-dione (4-OH-A) and 4-acetoxy-4-androstene-3,17-dione (4-Ac-A) on the 5 alpha-reduction of androgens in the rat prostate.

M. Motta, L. Martini, A. Brodie, 1986, Journal of steroid biochemistry.

Effects of new 17α-hydroxylase/C17,20-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo

V. Njar, D. Grigoryev, A. Brodie, 1999, British Journal of Cancer.

Aromatase inhibitors: introduction and perspective.

A. Brodie, 1990, Journal of enzyme inhibition.

Abstract 1072: MM-121/SAR256212, an anti-ErbB3 antibody, restores sensitivity to letrozole and delays the onset of resistance in an ER+ breast cancer model.

G. MacBeath, M. Curley, A. Brodie, 2013 .

Complete IGF Signaling Blockade by the Dual-Kinase Inhibitor, BMS-754807, Is Sufficient To Overcome Tamoxifen and Letrozole Resistance In Vitro and In Vivo.

F. Huang, P. Haluska, M. Gottardis, 2009 .

Antifertility effects of an aromatase inhibitor, 1,4,6-androstatriene-3, 17-dione.

A. Brodie, H. Brodie, J. Wu, 1979, Endocrinology.

Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement.

G. Colditz, P. Lønning, C. Osborne, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Neuroendocrine studies in hyperprolactinaemic male mice.

R. Clayton, A. Bartke, T. Parkening, 1987, The Journal of endocrinology.

Androgen receptor inactivation contributes to antitumor efficacy of 17α-hydroxylase/17,20-lyase inhibitor 3β-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer

Zhiyong Guo, Hong-Bin Fang, A. Khandelwal, 2008, Molecular Cancer Therapeutics.

Use of tissue-specific promoters in the regulation of aromatase cytochrome P450 gene expression in human testicular and ovarian sex cord tumors, as well as in normal fetal and adult gonads.

S. Bulun, E. Simpson, M. Kilgore, 1993, The Journal of clinical endocrinology and metabolism.

Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.

F. Huang, P. Haluska, M. Gottardis, 2011, Cancer research.

Docetaxel Followedby Castration Improves Outcomes in LNCaPProstate Cancer ^ Bearing Severe Combined

A. Hussain, A. Brodie, O. Goloubeva, 2005 .